Complete prevention of myocardial stunning, contracture, low-reflow, and edema after heart transplantation by blocking neutrophil adhesion molecules during reperfusion

J. G. Byrne, W. J. Smith, Michael Murphy, G. S. Couper, R. F. Appleyard, L. H. Cohn, D. C. Drinkwater

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

This study tested the hypothesis that preventing neutrophil adhesion during reperfusion, by blocking either the neutrophil membrane CD18 integrin complex or its endothelial and myocyte ligand, intercellular adhesion molecule-1 (ICAM-1), would reduce myocardial inflammation and edema and improve reflow and ventricular function after heart preservation and transplantation. After cardioplegia and insertion of a left ventricular balloon, rabbit hearts were heterotopically transplanted into recipient rabbits either immediately (immediate, n = 12) or after preservation in 4° C saline (3 hours of ischemia, n = 33). Forty-five minutes before reperfusion, recipients of preserved hearts received intravenous infusions of either saline (vehicle, n = 13), anti-CD18 monoclonal antibody (Mab) R15.7 (2 mg/kg) (anti-CD18, n = 10), or anti-ICAM-1 Mab R1.1 (2 mg/kg) (anti-ICAM, n = 10). During 3 hours of reperfusion the slope of the peak-systolic pressure-volume relation and its volume-axis intercept, the exponential elastic coefficient of the end-diastolic pressure-volume relation, the unstressed ventricular volume, and the time constant of the exponential left ventricular pressure decay after dP/dt(min) were serially measured. Myocardial blood flow was measured with microspheres from which coronary vascular resistance was calculated. After explantation, the degree of myocardial inflammation, estimated by tissue neutrophil sequestration (myeloperoxidase assay) and myocardial water content were determined. Within each group no significant differences in measurements made at 1, 2, and 3 hours of reperfusion were noted. Compared with the immediate transplantation group, the vehicle group demonstrated a significant increase in myeloperoxidase activity (3380 ± 456 versus 1712 ± 552 μU/gm, p <0.05), coronary vascular resistance (115.5 ± 13.4 versus 70.5 ± 10.6 U/gm, p <0.05), and myocardial water content (79.8% ± 0.4% versus 75.6% ± 1.3%, p <0.05), a significant decrease in unstressed ventricular volume (a leftward shift in the end-diastolic pressure-volume relation) (-0.49 ± 0.24 versus 0.28 ± 0.21 ml, p <0.05), and a marked prolongation in exponential left ventricular pressure delay after dP/dt(min) (156.64 ± 3.81 versus 37.25 ± 3.34 msec, p <0.01). The administration of either anti-CD18 or anti-ICAM-1 Mab prevented the increase in coronary vascular resistance (anti-CD18, 64.8 ± 4.5 versus 115.5 ± 13.4 U/gm, p <0.05; anti-ICAM, 52.3 ± 7.6 versus 115.5 ± 13.4 U/gm, p <0.05), the leftward shift in the end-diastolic pressure-volume relation (anti-CD18, 0.51 ± 0.43 versus -0.49 ± 0.24 ml, p <0.05; anti-ICAM, 0.70 ± 0.23 versus - 0.49 ± 0.24 ml, p <0.05), and the prolongation in exponential left ventricular pressure delay after dP/dt(min) (anti-CD18, 31.70 ± 4.36 versus 156.64 ± 3.81 msec, p <0.01; anti-ICAM, 27.26 ± 3.55 versus 156.64 ± 3.81 msec, p <0.01). However only anti-CD18 Mab significantly reduced myeloperoxidase activity (anti-CD18, 1100 ± 308 versus 3380 ± 456 μU/gm, p <0.05; anti-ICAM, 4830 ± 657 versus 3380 ± 456, p > 0.05) and myocardial water content (anti-CD18, 75.2% ± 1.7% versus 79.8% ± 0.4%, p <0.05; anti- ICAM, 78.2% ± 0.8% versus 79.8% ± 0.4%, p > 0.05). These results demonstrate the prevention of myocardial neutrophil sequestration, edema, the low-reflow phenomenon, and diastolic myocardial dysfunction by Mabs that block neutrophil adhesion. We conclude that neutrophil adhesion is an important mechanism of reperfusion-induced myocardial damage after heart transplantation and should be addressed in treatments directed at limiting reperfusion injury.

Original languageEnglish (US)
Pages (from-to)1589-1596
Number of pages8
JournalJournal of Thoracic and Cardiovascular Surgery
Volume104
Issue number6
StatePublished - 1992
Externally publishedYes

Fingerprint

Myocardial Stunning
Contracture
Heart Transplantation
Reperfusion
Edema
Neutrophils
Intercellular Adhesion Molecule-1
Peroxidase
Monoclonal Antibodies
Rabbits
Blood Pressure
Inflammation
Induced Heart Arrest
Myocardial Reperfusion
Ventricular Function
Water
Ventricular Pressure
Reperfusion Injury
Microspheres
Intravenous Infusions

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Complete prevention of myocardial stunning, contracture, low-reflow, and edema after heart transplantation by blocking neutrophil adhesion molecules during reperfusion. / Byrne, J. G.; Smith, W. J.; Murphy, Michael; Couper, G. S.; Appleyard, R. F.; Cohn, L. H.; Drinkwater, D. C.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 104, No. 6, 1992, p. 1589-1596.

Research output: Contribution to journalArticle

@article{56cfda9435de4ff48c670a2e4d7673f6,
title = "Complete prevention of myocardial stunning, contracture, low-reflow, and edema after heart transplantation by blocking neutrophil adhesion molecules during reperfusion",
abstract = "This study tested the hypothesis that preventing neutrophil adhesion during reperfusion, by blocking either the neutrophil membrane CD18 integrin complex or its endothelial and myocyte ligand, intercellular adhesion molecule-1 (ICAM-1), would reduce myocardial inflammation and edema and improve reflow and ventricular function after heart preservation and transplantation. After cardioplegia and insertion of a left ventricular balloon, rabbit hearts were heterotopically transplanted into recipient rabbits either immediately (immediate, n = 12) or after preservation in 4° C saline (3 hours of ischemia, n = 33). Forty-five minutes before reperfusion, recipients of preserved hearts received intravenous infusions of either saline (vehicle, n = 13), anti-CD18 monoclonal antibody (Mab) R15.7 (2 mg/kg) (anti-CD18, n = 10), or anti-ICAM-1 Mab R1.1 (2 mg/kg) (anti-ICAM, n = 10). During 3 hours of reperfusion the slope of the peak-systolic pressure-volume relation and its volume-axis intercept, the exponential elastic coefficient of the end-diastolic pressure-volume relation, the unstressed ventricular volume, and the time constant of the exponential left ventricular pressure decay after dP/dt(min) were serially measured. Myocardial blood flow was measured with microspheres from which coronary vascular resistance was calculated. After explantation, the degree of myocardial inflammation, estimated by tissue neutrophil sequestration (myeloperoxidase assay) and myocardial water content were determined. Within each group no significant differences in measurements made at 1, 2, and 3 hours of reperfusion were noted. Compared with the immediate transplantation group, the vehicle group demonstrated a significant increase in myeloperoxidase activity (3380 ± 456 versus 1712 ± 552 μU/gm, p <0.05), coronary vascular resistance (115.5 ± 13.4 versus 70.5 ± 10.6 U/gm, p <0.05), and myocardial water content (79.8{\%} ± 0.4{\%} versus 75.6{\%} ± 1.3{\%}, p <0.05), a significant decrease in unstressed ventricular volume (a leftward shift in the end-diastolic pressure-volume relation) (-0.49 ± 0.24 versus 0.28 ± 0.21 ml, p <0.05), and a marked prolongation in exponential left ventricular pressure delay after dP/dt(min) (156.64 ± 3.81 versus 37.25 ± 3.34 msec, p <0.01). The administration of either anti-CD18 or anti-ICAM-1 Mab prevented the increase in coronary vascular resistance (anti-CD18, 64.8 ± 4.5 versus 115.5 ± 13.4 U/gm, p <0.05; anti-ICAM, 52.3 ± 7.6 versus 115.5 ± 13.4 U/gm, p <0.05), the leftward shift in the end-diastolic pressure-volume relation (anti-CD18, 0.51 ± 0.43 versus -0.49 ± 0.24 ml, p <0.05; anti-ICAM, 0.70 ± 0.23 versus - 0.49 ± 0.24 ml, p <0.05), and the prolongation in exponential left ventricular pressure delay after dP/dt(min) (anti-CD18, 31.70 ± 4.36 versus 156.64 ± 3.81 msec, p <0.01; anti-ICAM, 27.26 ± 3.55 versus 156.64 ± 3.81 msec, p <0.01). However only anti-CD18 Mab significantly reduced myeloperoxidase activity (anti-CD18, 1100 ± 308 versus 3380 ± 456 μU/gm, p <0.05; anti-ICAM, 4830 ± 657 versus 3380 ± 456, p > 0.05) and myocardial water content (anti-CD18, 75.2{\%} ± 1.7{\%} versus 79.8{\%} ± 0.4{\%}, p <0.05; anti- ICAM, 78.2{\%} ± 0.8{\%} versus 79.8{\%} ± 0.4{\%}, p > 0.05). These results demonstrate the prevention of myocardial neutrophil sequestration, edema, the low-reflow phenomenon, and diastolic myocardial dysfunction by Mabs that block neutrophil adhesion. We conclude that neutrophil adhesion is an important mechanism of reperfusion-induced myocardial damage after heart transplantation and should be addressed in treatments directed at limiting reperfusion injury.",
author = "Byrne, {J. G.} and Smith, {W. J.} and Michael Murphy and Couper, {G. S.} and Appleyard, {R. F.} and Cohn, {L. H.} and Drinkwater, {D. C.}",
year = "1992",
language = "English (US)",
volume = "104",
pages = "1589--1596",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Complete prevention of myocardial stunning, contracture, low-reflow, and edema after heart transplantation by blocking neutrophil adhesion molecules during reperfusion

AU - Byrne, J. G.

AU - Smith, W. J.

AU - Murphy, Michael

AU - Couper, G. S.

AU - Appleyard, R. F.

AU - Cohn, L. H.

AU - Drinkwater, D. C.

PY - 1992

Y1 - 1992

N2 - This study tested the hypothesis that preventing neutrophil adhesion during reperfusion, by blocking either the neutrophil membrane CD18 integrin complex or its endothelial and myocyte ligand, intercellular adhesion molecule-1 (ICAM-1), would reduce myocardial inflammation and edema and improve reflow and ventricular function after heart preservation and transplantation. After cardioplegia and insertion of a left ventricular balloon, rabbit hearts were heterotopically transplanted into recipient rabbits either immediately (immediate, n = 12) or after preservation in 4° C saline (3 hours of ischemia, n = 33). Forty-five minutes before reperfusion, recipients of preserved hearts received intravenous infusions of either saline (vehicle, n = 13), anti-CD18 monoclonal antibody (Mab) R15.7 (2 mg/kg) (anti-CD18, n = 10), or anti-ICAM-1 Mab R1.1 (2 mg/kg) (anti-ICAM, n = 10). During 3 hours of reperfusion the slope of the peak-systolic pressure-volume relation and its volume-axis intercept, the exponential elastic coefficient of the end-diastolic pressure-volume relation, the unstressed ventricular volume, and the time constant of the exponential left ventricular pressure decay after dP/dt(min) were serially measured. Myocardial blood flow was measured with microspheres from which coronary vascular resistance was calculated. After explantation, the degree of myocardial inflammation, estimated by tissue neutrophil sequestration (myeloperoxidase assay) and myocardial water content were determined. Within each group no significant differences in measurements made at 1, 2, and 3 hours of reperfusion were noted. Compared with the immediate transplantation group, the vehicle group demonstrated a significant increase in myeloperoxidase activity (3380 ± 456 versus 1712 ± 552 μU/gm, p <0.05), coronary vascular resistance (115.5 ± 13.4 versus 70.5 ± 10.6 U/gm, p <0.05), and myocardial water content (79.8% ± 0.4% versus 75.6% ± 1.3%, p <0.05), a significant decrease in unstressed ventricular volume (a leftward shift in the end-diastolic pressure-volume relation) (-0.49 ± 0.24 versus 0.28 ± 0.21 ml, p <0.05), and a marked prolongation in exponential left ventricular pressure delay after dP/dt(min) (156.64 ± 3.81 versus 37.25 ± 3.34 msec, p <0.01). The administration of either anti-CD18 or anti-ICAM-1 Mab prevented the increase in coronary vascular resistance (anti-CD18, 64.8 ± 4.5 versus 115.5 ± 13.4 U/gm, p <0.05; anti-ICAM, 52.3 ± 7.6 versus 115.5 ± 13.4 U/gm, p <0.05), the leftward shift in the end-diastolic pressure-volume relation (anti-CD18, 0.51 ± 0.43 versus -0.49 ± 0.24 ml, p <0.05; anti-ICAM, 0.70 ± 0.23 versus - 0.49 ± 0.24 ml, p <0.05), and the prolongation in exponential left ventricular pressure delay after dP/dt(min) (anti-CD18, 31.70 ± 4.36 versus 156.64 ± 3.81 msec, p <0.01; anti-ICAM, 27.26 ± 3.55 versus 156.64 ± 3.81 msec, p <0.01). However only anti-CD18 Mab significantly reduced myeloperoxidase activity (anti-CD18, 1100 ± 308 versus 3380 ± 456 μU/gm, p <0.05; anti-ICAM, 4830 ± 657 versus 3380 ± 456, p > 0.05) and myocardial water content (anti-CD18, 75.2% ± 1.7% versus 79.8% ± 0.4%, p <0.05; anti- ICAM, 78.2% ± 0.8% versus 79.8% ± 0.4%, p > 0.05). These results demonstrate the prevention of myocardial neutrophil sequestration, edema, the low-reflow phenomenon, and diastolic myocardial dysfunction by Mabs that block neutrophil adhesion. We conclude that neutrophil adhesion is an important mechanism of reperfusion-induced myocardial damage after heart transplantation and should be addressed in treatments directed at limiting reperfusion injury.

AB - This study tested the hypothesis that preventing neutrophil adhesion during reperfusion, by blocking either the neutrophil membrane CD18 integrin complex or its endothelial and myocyte ligand, intercellular adhesion molecule-1 (ICAM-1), would reduce myocardial inflammation and edema and improve reflow and ventricular function after heart preservation and transplantation. After cardioplegia and insertion of a left ventricular balloon, rabbit hearts were heterotopically transplanted into recipient rabbits either immediately (immediate, n = 12) or after preservation in 4° C saline (3 hours of ischemia, n = 33). Forty-five minutes before reperfusion, recipients of preserved hearts received intravenous infusions of either saline (vehicle, n = 13), anti-CD18 monoclonal antibody (Mab) R15.7 (2 mg/kg) (anti-CD18, n = 10), or anti-ICAM-1 Mab R1.1 (2 mg/kg) (anti-ICAM, n = 10). During 3 hours of reperfusion the slope of the peak-systolic pressure-volume relation and its volume-axis intercept, the exponential elastic coefficient of the end-diastolic pressure-volume relation, the unstressed ventricular volume, and the time constant of the exponential left ventricular pressure decay after dP/dt(min) were serially measured. Myocardial blood flow was measured with microspheres from which coronary vascular resistance was calculated. After explantation, the degree of myocardial inflammation, estimated by tissue neutrophil sequestration (myeloperoxidase assay) and myocardial water content were determined. Within each group no significant differences in measurements made at 1, 2, and 3 hours of reperfusion were noted. Compared with the immediate transplantation group, the vehicle group demonstrated a significant increase in myeloperoxidase activity (3380 ± 456 versus 1712 ± 552 μU/gm, p <0.05), coronary vascular resistance (115.5 ± 13.4 versus 70.5 ± 10.6 U/gm, p <0.05), and myocardial water content (79.8% ± 0.4% versus 75.6% ± 1.3%, p <0.05), a significant decrease in unstressed ventricular volume (a leftward shift in the end-diastolic pressure-volume relation) (-0.49 ± 0.24 versus 0.28 ± 0.21 ml, p <0.05), and a marked prolongation in exponential left ventricular pressure delay after dP/dt(min) (156.64 ± 3.81 versus 37.25 ± 3.34 msec, p <0.01). The administration of either anti-CD18 or anti-ICAM-1 Mab prevented the increase in coronary vascular resistance (anti-CD18, 64.8 ± 4.5 versus 115.5 ± 13.4 U/gm, p <0.05; anti-ICAM, 52.3 ± 7.6 versus 115.5 ± 13.4 U/gm, p <0.05), the leftward shift in the end-diastolic pressure-volume relation (anti-CD18, 0.51 ± 0.43 versus -0.49 ± 0.24 ml, p <0.05; anti-ICAM, 0.70 ± 0.23 versus - 0.49 ± 0.24 ml, p <0.05), and the prolongation in exponential left ventricular pressure delay after dP/dt(min) (anti-CD18, 31.70 ± 4.36 versus 156.64 ± 3.81 msec, p <0.01; anti-ICAM, 27.26 ± 3.55 versus 156.64 ± 3.81 msec, p <0.01). However only anti-CD18 Mab significantly reduced myeloperoxidase activity (anti-CD18, 1100 ± 308 versus 3380 ± 456 μU/gm, p <0.05; anti-ICAM, 4830 ± 657 versus 3380 ± 456, p > 0.05) and myocardial water content (anti-CD18, 75.2% ± 1.7% versus 79.8% ± 0.4%, p <0.05; anti- ICAM, 78.2% ± 0.8% versus 79.8% ± 0.4%, p > 0.05). These results demonstrate the prevention of myocardial neutrophil sequestration, edema, the low-reflow phenomenon, and diastolic myocardial dysfunction by Mabs that block neutrophil adhesion. We conclude that neutrophil adhesion is an important mechanism of reperfusion-induced myocardial damage after heart transplantation and should be addressed in treatments directed at limiting reperfusion injury.

UR - http://www.scopus.com/inward/record.url?scp=0026719365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026719365&partnerID=8YFLogxK

M3 - Article

VL - 104

SP - 1589

EP - 1596

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 6

ER -